Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA.
Mailman Research Center, McLean Hospital, Belmont, MA, USA.
J Mol Neurosci. 2018 Sep;66(1):59-67. doi: 10.1007/s12031-018-1133-z. Epub 2018 Aug 9.
The atypical antipsychotic drug iloperidone has high affinity for a wide range of neurotransmitter receptors, including serotonin and adrenoceptors. We examined the long-term effects of multiple doses of iloperidone (0.5, 1.5, or 5 mg/kg) on serotonin (5-HT) 5-HT, 5-HT receptor subtypes, and adrenoceptors α and α subtypes. Rats received daily intraperitoneal injections of different doses of iloperiodone or vehicle for 4 weeks. Receptor autoradiography quantified the levels of 5-HT and adrenoceptors in medial prefrontal cortex (MPC), dorsolateral frontal cortex (DFC), caudate putamen (CPu), nucleus accumbens (NAc), and hippocampal CA1 (HIP-CA1) and CA3 (HIP-CA3) regions. Four weeks of iloperidone treatment significantly and dose-dependently increased 5-HT and decreased 5-HT receptors in the MPC and DFC. Higher doses of iloperidone (1.5 and 5 mg/kg) increased 5-HT and decreased 5-HT receptors in HIP-CA1 and HIP-CA3 regions. In addition, repeated iloperidone treatment produced significant increases in α- and α-adrenoceptors in MPC, DFC, HIP-CA1, and HIP-CA3 regions. No changes in 5-HT and adrenoceptors were observed in other brain regions examined. These results suggest that long-term iloperidone treatment exerts region- and dose-specific effects on forebrain 5-HT and adrenoceptors, which may contribute to its therapeutic benefits in improving positive and negative symptoms of schizophrenia as well as maintaining a benign safety profile.
非典型抗精神病药物依洛哌酮对广泛的神经递质受体具有高亲和力,包括 5-羟色胺(5-HT)和肾上腺素受体。我们研究了依洛哌酮(0.5、1.5 或 5mg/kg)多次给药对 5-HT、5-HT 受体亚型和肾上腺素受体α和α亚型的长期影响。大鼠接受不同剂量依洛哌酮(0.5、1.5 或 5mg/kg)或载体的每日腹腔注射,共 4 周。受体放射自显影定量分析了内侧前额叶皮层(MPC)、背外侧前额叶皮层(DFC)、尾状核(CPu)、伏隔核(NAc)和海马 CA1(HIP-CA1)和 CA3(HIP-CA3)区域中 5-HT 和肾上腺素受体的水平。4 周的依洛哌酮治疗显著且剂量依赖性地增加了 MPC 和 DFC 中的 5-HT 和减少了 5-HT 受体。较高剂量的依洛哌酮(1.5 和 5mg/kg)增加了 HIP-CA1 和 HIP-CA3 区域中的 5-HT,并减少了 5-HT 受体。此外,重复的依洛哌酮治疗使 MPC、DFC、HIP-CA1 和 HIP-CA3 区域中的α-和α-肾上腺素受体显著增加。在其他检查的脑区未观察到 5-HT 和肾上腺素受体的变化。这些结果表明,长期依洛哌酮治疗对前脑 5-HT 和肾上腺素受体具有区域和剂量特异性作用,这可能有助于其治疗精神分裂症阳性和阴性症状以及维持良性安全性的益处。